Q. Zheng

Development of the generic drug industry in the US after the Hatch-Waxman Act of 1984

G. Boehm, Lixin Yao, Liang Han, 2013 .

Cost of Blood and Body Fluid Occupational Exposure Management in Beijing, China

Daifang Wang, Q. Zheng, Y. Ye, 2020, International journal of environmental research and public health.

A Cost-effectiveness Analysis of iGlarLixi Versus IDegAsp and Appropriate Price Exploration of iGlarLixi for Type 2 Diabetes Mellitus Patients in China

Yanqing Jiang, J. Xuan, Jianxin Pang, 2023, Clinical Drug Investigation.

Factors to consider in developing individual pharmaceutical product quality risk profiles useful to government procurement agencies

Wei Xu, G. Boehm, Q. Zheng, 2015, Acta pharmaceutica Sinica. B.

Encouraging an Environment for Pharmaceutical R&D in China

Donglei Mao, Qiang Zheng, Donglei Mao, 2009, Journal of Pharmaceutical Innovation.

Evidence-based decision-making on medical technologies in China, Japan, and Singapore.

Takashi Fukuda, Isao Kamae, Gordon Liu, 2009, Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research.

Quantitative Analysis of the QMS for Pharmaceutical Manufacturing

Qiang Zheng, Guoxu Wang, Weibing Wang, 2021, Journal of Pharmaceutical Innovation.